natgillin/translations-raw huggingface dataset:
The incidence of these AEs was also high in the placebo groups.
Pojavnost teh neželenih učinkov je bila visoka tudi skupini, ki je prejemala placebo.
The incidence of these events was more common in patients with lower pre-treatment FEV1; 29.6% and 37.7% among patients with ppFEV1
Incidenca teh dogodkov je bila večja pri bolnikih, ki so imeli pred zdravljenjem manjši FEV1; 29,6 % oziroma
The incidence of these reactions in some clinical trials of Avastin is common (up to 5% in bevacizumab- treated patients).
Incidenca teh reakcij pri nekaterih kliničnih preskušanjih zdravila Avastin je pogosta (do 5 % pri bolnikih, zdravljenih z bevacizumabom).
The incidence of thrombocytopenia was higher in the Gazyvaro plus chlorambucil arm (15%) compared to the rituximab plus chlorambucil arm especially during the first cycle.
Incidenca trombocitopenije je bila s kombinacijo zdravila Gazyvaro in klorambucila večja kot s kombinacijo rituksimaba in klorambucila, še zlasti v prvem ciklusu.
The incidence of thrombocytopenia was low ( <1% , grade 3/4 ) and was not different between treatment arms.
Incidenca trombocitopenije je bila nizka (< 1 % 3. ali 4. stopnje) in se med zdravljenima skupinama ni razlikovala.
The incidence of thrombocytopenia was low (<1 %, grade 3/4) and was not different between treatment arms.
Incidenca trombocitopenije je bila nizka (< 1 % 3. ali 4. stopnje) in se med zdravljenima skupinama ni razlikovala.
The incidence of thrombocytopenia was low (<1%, grade 3/4%) and was not different between treatment arms.
Incidenca trombocitopenije je bila nizka (< 1 % 3. ali 4. stopnje) in se med zdravljenima skupinama ni razlikovala.
The incidence of thrombocytopenia was lower in the Gazyvaro plus bendamustine (G+B) arm (15%) compared to the bendamustine (B) alone arm (24%).
Incidenca trombocitopenije je bila s kombinacijo zdravila Gazyvaro in bendamustina (G + B) manjša (15 %) kot pri samostojni uporabi bendamustina (B) (24 %).
The incidence of thyroid events was higher in patients with a medical history of thyroid disorders both in the LEMTRADA and interferon beta 1a (IFNB-1a) treatment groups.
Pojavnost dogodkov, povezanih s ščitnico, je bila večja pri bolnikih z anamnezo bolezni ščitnice, tako v skupini, zdravljeni z zdravilom LEMTRADA, kot v skupini, zdravljeni z interferonom beta 1a (IFNB-1a).
The incidence of vomiting on the day of, or the day after, dosing has been observed to increase as a function of dose.
Opazili so, da pojav bruhanja na dan dajanja zdravila ali dan po dajanju narašča z odmerkom.
The incidence of weight loss of ≥ 7 % from baseline to last visit was 6.4 % for Abilify Maintena and 6.7 % for placebo.
Incidenca zmanjšanja telesne mase ≥ 7 % od izhodiščne vrednosti do zadnjega obiska je znašala 6,4 % pri zdravilu Abilify Maintena in 6,7 % pri placebu.
The incidence of withdrawal due to adverse events during the 30-week controlled trial was 6 % for prolonged-release exenatide treated patients, 5 % for immediate-release exenatide treated patients.
Incidenca prekinitve zdravljenja zaradi neželenih učinkov v 30-tedenskih kontroliranih preskušanjih je bila pri bolnikih, zdravljenih z eksenatidom v obliki s podaljšanim sproščanjem, 6 % in pri bolnikih, zdravljenih z eksenatidom v obliki s takojšnim sproščanjem, 5 %.
The incidence of withdrawal due to adverse reactions was 7.8% for liraglutide­treated patients and 3.4% for comparator­treated patients in the long­term controlled trials (26 weeks or longer).
V dolgotrajnih kontroliranih preskušanjih (26 tednov ali dlje) je bilo zaradi neželenih učinkov zdravljenje prekinjeno pri 7,8 % bolnikov, ki so se zdravili z liraglutidom, in pri 3,4 % bolnikov, ki so prejemali primerjalno zdravilo.
The incidence of Xiapex-associated pruritus increased after more Xiapex injections in patients with Dupuytren’s contracture.
Incidenca pruritusa, povezanega z zdravilom Xiapex, se je pri bolnikih z Dupuytrenovo kontrakturo po več injekcijah zdravila Xiapex povečala.
The incidence of YMDD mutant HBV was similar to that observed in adults, ranging from 19 % at week 52 up to 45 % in patients treated continuously for 24 months.
Pojavnost YMDD mutanta HBV je bila podobna tisti, ki so jo opazili pri odraslih, v obsegu od 19 % v 52. tednu do 45 % pri bolnikih, ki so se neprekinjeno zdravili 24 mesecev.
The incidence per 100 subject-years of all serious infections was 4.3; 95% CI: 3.8, 4.8, in patients receiving golimumab 100 mg and 2.6; 95% CI: 2.1, 3.2, in patients receiving golimumab 50 mg.
Incidenca vseh resnih okužb na 100 preiskovanec-let je bila 4,1; 95 % IZ: 3,6, 4,5, pri bolnikih, ki so prejemali golimumab v odmerku 100 mg, in 2,5; 95 % IZ: 2,0, 3,1, pri bolnikih, ki so prejemali golimumab v odmerku 50 mg.
The incidence rate did not increase for malignancies overall, by major type (non-melanomatous skin cancer, solid tumors, and hematologic malignancies), or for individual tumor types in the double blind and open label period compared to the double-blind experience.
Med dvojno slepim in odprtim obdobjem kliničnih preskušanj stopnja pojavnosti vseh novotvorb ni bila večja od stopnje pojavnosti med dvojno slepim obdobjem, in sicer tako glede na glavne (nemelanomski rak kože, solidni tumorji in hematološke oblike raka) kot posamezne oblike tumorjev.
The incidence rate of new cases of infections in placebo-controlled clinical trials in rheumatoid arthritis was 1.03 per patient-year for all Cimzia-treated patients and 0.92 per patient-year for placebo-treated patients.
V s placebom nadzorovanih kliničnih študijah pri revmatoidnem artritisu je bila pri bolnikih, ki so prejemali zdravilo Cimzia, pogostnost novih okužb 1,03 na bolnikovo leto, pri bolnikih, ki so prejemali placebo, pa 0,92 na bolnikovo leto.
The incidence rate of observed malignancies was consistent with that expected in an age- and gender- matched rheumatoid arthritis population (see section 4.4).
Stopnja pojavnosti opaženih novotvorb je bila v skladu s po starosti in spolu pričakovano stopnjo pri populaciji z revmatoidnim artritisom (glejte poglavje 4.4).
The incidence rates for the primary safety outcome (major or clinically relevant non-major bleeding events) were slightly lower in the rivaroxaban treatment group (10.3% (249/2412)) than in the enoxaparin/VKA treatment group (11.4% (274/2405)).
Incidenca za primarni varnostni izid (velike ali klinično pomembne majhne krvavitve) je bila rahlo nižja v skupini, ki je prejemala rivaroksaban (10,3 % (249/2412)) kot v skupini, ki je prejemala enoksaparin/antagoniste vitamina K (11,4 % (274/2405)).
The incidence rates for the principal safety outcome (major and non-major clinically relevant bleeding events) were similar for both treatment groups (see Table 4).
Pojavnost glavnega varnostnega izida (velike in klinično pomembne majhne krvavitve) je bila podobna v obeh skupinah bolnikov (glejte preglednico 4).
The incidence rates for the principal safety outcome (non-CABG TIMI major bleeding events) were higher in patients treated with Xarelto than in patients who received placebo (see Table 5).
Incidenca glavnega izida varnosti (velika krvavitev, ki ni v povezavi s CABG TIMI) je bila višja pri bolnikih, zdravljenih z zdravilom Xarelto, kot pri bolnikih, ki so prejemali placebo (glejte preglednico 5).
The incidence rates per 100 patient-years were 0.73 for non-melanomatous skin cancer, 0.59 for solid malignancies and 0.13 for hematologic malignancies.
Stopnja pojavnosti na 100 bolniških let je bila 0,73 za nemelanomski rak kože, 0,59 za solidne tumorje in 0,13 za hematološke oblike raka.
the incidences of all-cause mortality, major cardiovascular events, new
mora biti zasnovana tako, da bo lahko primerjala pojavnost umrljivosti
The incidences of documented symptomatic hypoglycaemia when dulaglutide 0.75 mg and 1.5 mg, respectively, were used in combination with a sulphonylurea and metformin were 39.0% and 40.3% and the rates were 1.67 and 1.67 events/patient/year.
Pogostnost dokumentirane simptomatske hipoglikemije ob uporabi dulaglutida 0,75 mg in 1,5 mg v kombinaciji s sulfonilsečnino in metforminom je bila 39,0 % oziroma 40,3 %, stopnje pa 1,67 oziroma
The incidences of documented symptomatic hypoglycaemia when dulaglutide 0.75 mg and 1.5 mg, respectively, were used in combination with a sulphonylurea and metformin were 39.0% and 40.3% and the rates were 1.67 and 1.67 events/patient/year.
Stopnja dokumentirane simptomatske hipoglikemije za zdravilo Trulicity 1,5 mg in 0,75 mg in metformin je bila 0,62, 0,15, in 0,09 epizod/bolnika/leto.
The incidences of embryo-foetal loss were 33, 50, and
Incidence izgube zarodka so bile 33-% pri brejih samicah, ki so jih zdravili na dva tedna z odmerkom pertuzumaba
The incidences of Grade ≥3 neutropenia were higher in the high-trifluridine AUC group (47.8%) compared with the low-trifluridine AUC group (30.4%).
Pojavnost nevtropenije ≥ 3. stopnje je bila večja v skupini z večjim AUC trifluridina (47,8 %) kot v skupini z manjšim AUC trifluridina (30,4 %).
The incidences of the ADRs associated with aripiprazole therapy are tabulated below.
V spodnji preglednici so navedene pojavnosti ADR, povezane z zdravljenjem z aripiprazolom.
The incidences of these reactions in these studies showed no difference between the palivizumab and placebo groups and the reactions were not drug related.
V pogostnosti teh učinkov v teh študijah med skupinama na palivizumabu in placebu ni bilo razlik in učinki niso bili povezani z zdravilom.
The incident light dose is 20 J/cm2, delivered at an irradiance of 100 mW/cm2 to the tumour surface, implying an illumination time of approximately 200 seconds.
Odmerek vpadne svetlobe je 20 J/cm2 pri iradiaciji 100 mW/cm2 na površino tumorja in pri času obsevanja približno 200 sekund.
The incident light dose is 20 J/cm2, delivered by the microlens fibre-optic in a circular field to the tumour surface at an irradiance of 100 mW/cm2, implying an illumination time of 200 seconds.
Odmerek vpadne svetlobe je 20 J/cm2, pri iradiaciji z močjo 100 mW/cm2 na površino tumorja in pri času obsevanja približno 200 sekund.
The incorporation of 5-FU also leads to inhibition of RNA and protein synthesis.
Vgraditev 5- FU zavira tudi sintezo RNA in proteinov.
The increase from baseline in lumbar spine and femoral neck BMD was 6.8 and 2.2, respectively in patients treated with Preotact.
Pri bolnicah, zdravljenih z zdravilom Preotact, se je BMD ledvenega predela hrbtenice povečal za 6,8%, BMD femoralnega vratu pa za 2,2% nad izhodiščnimi vrednostmi.
The increase in 24-hour urine volume was dose dependent.
Povečanje 24-urnega volumna urina je bilo odvisno od odmerka.
The increase in AUC∞, AUCt, and Cmax is of 111.88%, 114.06%, and 115.28% respectively.
Povečanje vrednosti AUC∞, AUCt in Cmax znaša 111,88 %, 114,06 % in 115,28 %.
The increase in efavirenz pharmacokinetic parameters is not considered clinically significant.
Povečanje farmakokinetičnih parametrov efavirenza se ne smatra za klinično pomembno.
The increase in exposure was similar regardless of meal type (e.g., high-fat versus moderate-fat) or calorie content (approximately 600 Kcal versus approximately 1000 Kcal).
Povečanje izpostavljenosti je bilo podobno ne glede na vrsto obroka (npr. zelo masten obrok v primerjavi z zmerno mastnim) ali kalorično vrednost (približno 600 kcal v primerjavi s približno 1000 kcal).
The increase in mean AUC is linear and dose proportional in the therapeutic range.
Večanje povprečne AUC je linearno in sorazmerno odmerkom v terapevtskem območju..
The increase in mean AUC with increasing dose was linear and dose proportional in the range of 25-1,000 mg imatinib after oral administration.
Zvečevanje povprečne AUC z večanjem odmerka je bilo po peroralnem dajanju linearno in sorazmerno odmerku v območju 25–1000 mg imatiniba.
The increase in mean AUC with increasing dose was linear and dose proportional in the range of 25–1,000 mg imatinib after oral administration.
Zvečevanje povprečne AUC z večanjem odmerka je bilo po peroralnem dajanju linearno in sorazmerno odmerku v območju 25–1.000 mg imatiniba.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Podaljšanje preţivetja, opaţeno v kraku s tedenskim odmerjanjem docetaksela, ni bilo statistično značilno v primerjavi s kontrolnim krakom z mitoksantronom.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Podaljšanje preživetja, opaženo v kraku s tedenskim odmerjanjem docetaksela, ni bilo statistično značilno v primerjavi s kontrolnim krakom z mitoksantronom.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Povečanje v preživetju opazovano pri kraku tedenskega docetaksela ni bilo statistično značilno v primerjavi z mitoksantronovem kontrolnem kraku zdravljenja.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Povečanje v preživetju opazovano pri kraku tedenskega docetaksela ni bilo statistično značilno v primerjavi z mitoksantronovim kontrolnim krakom zdravljenja.
The increase in survival seen in the docetaxel weekly arm was not statistically significant compared to the mitoxantrone control arm.
Povečanje v preživetju opazovano pri roki tedenskega docetaksela ni bilo statistično značilno v primerjavi z mitoksantronovo kontrolno roko zdravljenja.
The increase in vilanterol exposure was not associated with an increase in beta2- agonist related systemic effects on heart rate, blood potassium or QTcF interval.
Večje izpostavljenosti vilanterolu ni spremljalo povečanje z agonistom adrenergičnih receptorjev beta2 povezanih sistemskih učinkov na srčno frekvenco, raven kalija v krvi ali interval QTcF.
The increase is approximately 1.5 to 2-fold, corresponding to a 1.5-fold elevation of plasma AGP, to which imatinib binds strongly.
Gre za približno 1,5 do 2-kratno zvišanje, ki ustreza 1,5- kratnemu zvišanju alfa kislega proteina v plazmi, na katerega se imatinib močno veže.
The increase of alkaline phosphatase by glucocorticoids could be related to enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.
Zvišanje ravni alkalne fosfataze, ki ga povzročajo glukokortikoidi, je lahko povezano s povečanjem jeter (hepatomegalijo) z zvišano koncentracijo jetrnih encimov v serumu.
The increase was statistically significant in this study (p=0.022).
V slednji študiji je bilo povečanje statistično značilno p = 0,022.
The increased digoxin level may lessen over time as Pgp induction develops.
Ob tem se virološka učinkovitost v primerjavi s standardnimi odmerki fosamprenavirja/ritonavirja ni povečala.
The increased digoxin level may lessen over time as Pgp induction develops.
Zvišana koncentracija digoksina se sčasoma lahko zniža, ko se razvije indukcija Pgp.
The increased dose interval for emtricitabine/tenofovir disoproxil in HIV-1 infected patients with moderate renal impairment is expected to result in higher peak plasma concentrations and lower Cmin levels as compared to patients with normal renal function.
Pričakuje se, da se bo odmerjanje emtricitabina / dizoproksiltenofovirata v daljših časovnih intervalih za bolnike s HIV–1 z zmerno ledvično okvaro odražalo v višjih najvišjih plazemskih koncentracijah in nižjih nivojih Cmin v primerjavi z posameznikih z normalno ledvično funkcijo.
The increased dose interval for Truvada in HIV-1 infected patients with moderate renal impairment is expected to result in higher peak plasma concentrations and lower Cmin levels as compared to patients with normal renal function.
Pričakuje se, da se bo odmerjanje zdravila Truvada v daljših časovnih intervalih za bolnike s HIV–1 z zmerno ledvično okvaro odražalo v višjih maksimalnih plazemskih koncentracijah in nižjih nivojih Cmin v primerjavi z bolniki z normalno ledvično funkcijo.
The increased dose of 10 mg is recommended when the medicine is used with tadalafil (another medicine for PAH).
Povečani 10-miligramski odmerek se priporoča, kadar se zdravilo Volibirs uporablja v kombinaciji s tadalafilom (drugim zdravilom za zdravljenje pljučne arterijske hipertenzije).
The increased efavirenz concentrations observed following administration with food may lead to an increase in frequency of adverse reactions (see sections 4.4 and 5.2).
Povišana koncentracija efavirenza, ki so jo opazili po zaužitju zdravila Efavirenz s hrano, lahko vodi do povečane pogostosti neželenih učinkov (glejte poglavji 4.4 in 5.2).
The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil fumarate, including renal disorders.
Povečana izpostavljenost tenofovirja lahko potencira neželene reakcije, povezane z dizoproksiltenofovirijevim fumaratom, vključno z ledvičnimi boleznimi.
The increased exposure of tenofovir could potentiate adverse reactions associated with tenofovir disoproxil fumarate, including renal disorders.
Povečana izpostavljenost tenofovirja lahko potencira neželene reakcije, povezane z dizoproksiltenofovirijevim fumaratom, vključujoč motnje v delovanju ledvic.
The increased exposure of tenofovir could potentiate tenofovir- associated adverse events, including renal disorders.
Večja izpostavljenost tenofovirju bi lahko okrepila neželene učinke, povezane s tenofovirjem, vključno z ledvičnimi boleznimi.
The increased exposure of tenofovir could potentiate tenofovir-associated adverse events, including renal disorders.
Večja izpostavljenost tenofovirju bi lahko okrepila neželene učinke, povezane s tenofovirjem, vključno z ledvičnimi boleznimi.
The increased risk of overall and major hypoglycemia was primarily observed in subjects with A1C < 7% at baseline.
Večje tveganje za vse hipoglikemije in hujše hipoglikemije so ugotovili predvsem med preiskovanci, ki so imeli izhodiščno A1c < 7 %.
The increased risk of overall and major hypoglycemia was primarily observed in subjects with A1C <7% at baseline.
Večje tveganje za vse hipoglikemije in hujše hipoglikemije so ugotovili predvsem med preiskovanci, ki so imeli izhodiščno A1c < 7 %.
The increased risk of overall hypoglycemia and major hypoglycemia observed in the saxagliptin-treated group occurred primarily in subjects treated with SU at baseline and not in subjects on insulin or metformin monotherapy at baseline.
Večje tveganje za vse hipoglikemije in hujše hipoglikemije, ugotovljeno med prejemniki saksagliptina, so imeli predvsem bolniki, ki so izhodiščno dobivali sulfonilsečnino, ne pa bolniki, ki so izhodiščno dobivali monoterapijo z insulinom ali metforminom.
The increases in BMD were significantly greater in the Aclasta-treated group at the lumbar spine and femoral neck at 12 months compared to risedronate (all p<0.03).
Po 12 mesecih je bilo povečanje mineralne gostote kosti ledvene hrbtenice in vratu stegnenice statistično značilno večje v skupini bolnikov, ki so prejemali zdravilo Aclasta, v primerjavi s tistimi, ki so prejemali risedronat (vse vrednosti p < 0,03).
The increases in BMD were significantly greater in the zoledronic acid-treated group at the lumbar spine and femoral neck at 12 months compared to risedronate (all p<0.03).
Po 12 mesecih je bilo povečanje mineralne gostote kosti ledvene hrbtenice in vratu stegnenice statistično značilno večje v skupini bolnikov, ki so prejemali zoledronsko kislino, v primerjavi s tistimi, ki so prejemali risedronat (vse vrednosti p <0,03).
The increases in enteral nutritional volume corresponded to increases in enteral calories, which were highest at the recommended dose.
Zvečanje volumna enteralne prehrane je ustrezalo zvečanju enteralnih kalorij, ki je bilo največje pri priporočenem odmerku.
The independent review of patient scans confirmed the findings of the investigator assessment of PFS.
Neodvisni pregled slik bolnikov je potrdil ugotovitve ocen raziskovalcev o preživetju brez napredovanja bolezni.
The indication for NeoRecormon treatment and, if given, the single dose should be determined from the required amount of pre-donated blood and the endogenous red cell reserve according to the following graphs.
Indikacijo za zdravljenje z zdravilom NeoRecormon, in, če je zdravljenje indicirano, enkratni odmerek, določimo glede na potrebno količino vnaprej darovane krvi in endogeno rezervo rdečih krvničk po naslednjih diagramih:
The indication for NeoRecormon treatment of nephrosclerotic patients not yet undergoing dialysis should be defined individually, as a possible acceleration of progression of renal failure cannot be ruled out with certainty.
Pri bolnikih z nefrosklerozo, ki se še ne zdravijo z dializo, moramo indikacijo za zdravljenje z zdravilom NeoRecormon določati individualno, ker morebitnega progresivnega razvoja ledvične odpovedi ni mogoče z gotovostjo izključiti.
The indication for treatment with NeoRecormon and, if given, the single dose should be determined from the required amount of pre-donated blood and the endogenous red cell reserve according to the following graphs.
Indikacijo za zdravljenje z zdravilom NeoRecormon, in, če je zdravljenje indicirano, enkratni odmerek, določimo glede na potrebno količino vnaprej darovane krvi in endogeno rezervo rdečih krvničk po naslednjih diagramih:
The indication in paediatric patients is based on 48-week analyses of a single-arm, Phase II trial in antiretroviral treatment-experienced paediatric patients (see section 5.1).
Indikacija pri otrocih temelji na analizah podatkov po 48. tednih preskušanja II. faze z eno skupino pediatričnih bolnikov, ki so se že zdravili s protiretrovirusnimi zdravili (glejte poglavje 5.1).
The indication is based on clinical studies of naturally occurring influenza in which the predominant infection was influenza A.
Indikacija temelji na kliničnih študijah gripe, ki se pojavlja naravno, in pri kateri kjer je bila glavna okužba z virusom influence tipa A.
The indication is based on the demonstration of efficacy of Silgard in females 16 to 45 years of age and in males 16 to 26 years of age and on the demonstration of immunogenicity of Silgard in 9- to 15-year old children and adolescents.
Indikacija temelji na dokazu učinkovitosti cepiva Silgard pri ženskah, starih 16 do 45 let, in moških, starih 16 do 26 let, ter dokazu imunogenosti cepiva Silgard pri 9 do 15 let starih otrocih in mladostnikih.
The indication of Gardasil 9 is based on: non-inferior immunogenicity between Gardasil 9 and the qHPV vaccine for HPV Types 6, 11, 16 and 18 in girls 9 to 15 years of age, women and men 16 to 26 years of age; consequently, efficacy for Gardasil 9 against persistent infection and disease related to HPV Types 6, 11, 16, or 18 can be inferred to be comparable to that of the qHPV vaccine. demonstration of efficacy against persistent infection and disease related to HPV Types 31, 33, 45, 52 and 58 in girls and women 16 to 26 years of age, and demonstration of non-inferior immunogenicity against the Gardasil 9 HPV Types in boys and girls 9 to 15 years of age and men 16 to 26 years of age, compared to girls and women 16 to 26 years of age.
Indikacija za cepivo Gardasil 9 temelji na: neinferiorni imunogenosti cepiva Gardasil 9 v primerjavi s qHPV cepivom za tipe HPV 6, 11, 16 in 18 pri deklicah, starih od 9 do 15 let, ter ženskah in moških, starih od 16 do 26 let; glede na to je mogoče sklepati, da je učinkovitost cepiva Gardasil 9 proti persistentni okužbi in bolezni, povezani s tipi HPV 6, 11, 16 in 18, podobna učinkovitosti qHPV cepiva, dokazani učinkovitosti proti persistentni okužbi in bolezni, povezani s tipi HPV 31, 33, 45, 52 in 58 pri deklicah in ženskah, starih od 16 do 26 let, in dokazani neinferiorni imunogenosti za tipe HPV v cepivu Gardasil 9 pri dečkih in deklicah, starih od 9 do 15 let, ter moških, starih od 16 do 26 let, v primerjavi z deklicami in ženskami, starimi od 16 do 26 let.
The individual dose of pramipexole should be in the range of 0.264 mg of base (0.375 mg of salt) to a maximum of 3.3 mg of base (4.5 mg of salt) per day.
Odmerek pramipeksola za posameznega bolnika naj bo v razponu od 0,264 mg pramipeksola (0,375 mg soli) do največ 3,3 mg pramipeksola (4,5 mg soli) na dan.